Evidence map›Paper›PMID 28181487›Full record

SynthesisScientific reports2017

A Role for Photobiomodulation in the Prevention of Myocardial Ischemic Reperfusion Injury: A Systematic Review and Potential Molecular Mechanisms.

Ann Liebert, Andrew Krause, Neil Goonetilleke, Brian Bicknell, Hosen Kiat

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05160519 (Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes Among Individuals With Acute Coronary Syndrome), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05160519 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes Among Individuals With Acute Coronary Syndrome

TypeinterventionalSponsorAsir John SamuelRan2022 to 2023Enrolled60ConditionsAcute Coronary SyndromeArmsClass IV Laser, Sham Class IV Laser
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease.International journal of molecular sciences · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Ann LiebertAustralasian Research Institute, Wahroonga, Australia.
Andrew KrauseMaitland Hospital, Maitland, Australia.
Neil GoonetillekeSydney University, Sydney, Australia.
Brian BicknellAustralasian Research Institute, Wahroonga, Australia.
Hosen KiatUniversity of New South Wales, Kensington, Australia.
Australian Catholic University · AUBlacktown & Mount Druitt Hospital · AUThe University of Sydney · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia reperfusion injury is a negative pathophysiological event that may result in cardiac cell apoptosis and is a result of coronary revascularization and cardiac intervention procedures. The resulting loss of cardiomyocyte cells and the formation of scar tissue, leads to impaired heart function, a major prognostic determinant of long-term cardiac outcomes. Photobiomodulation is a novel cardiac intervention that has displayed therapeutic effects in reducing myocardial ischemia reperfusion related myocardial injury in animal models. A growing body of evidence supporting the use of photobiomodulation in myocardial infarct models has implicated multiple molecular interactions. A systematic review was conducted to identify the strength of the evidence for the therapeutic effect of photobiomodulation and to summarise the current evidence as to its mechanisms. Photobiomodulation in animal models showed consistently positive effects over a range of wavelengths and application parameters, with reductions in total infarct size (up to 76%), decreases in inflammation and scarring, and increases in tissue repair. Multiple molecular pathways were identified, including modulation of inflammatory cytokines, signalling molecules, transcription factors, enzymes and antioxidants. Current evidence regarding the use of photobiomodulation in acute and planned cardiac intervention is at an early stage but is sufficient to inform on clinical trials.

Indexed as

AnimalsAntioxidantsBiasBiomarkersCytokinesCytoskeletonDose-Response Relationship, RadiationHumansInflammation MediatorsIntercellular Signaling Peptides and ProteinsLow-Level Light TherapyMitochondriaMyocardial Reperfusion InjuryOxidation-ReductionRiskSignal TransductionAntioxidantsBiomarkersCytokinesInflammation MediatorsIntercellular Signaling Peptides and Proteins

Identifiers

PMID28181487
PMCPMC5299427
OpenAlexW2587163031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.